Navigation Links
Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Date:8/7/2008

MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, during a late breaker session at the XVII International AIDS Conference in Mexico City.

"We are extremely pleased that the final results of the Phase 2a study presented today demonstrate that 800 mg once daily produced similar viral load reductions as 400 mg twice daily, providing final confirmation that RDEA806 works equally well given either once or twice daily. Based on the data to date, we continue to believe that RDEA806 has the potential to be a first-line therapy for the treatment of HIV," said Barry D. Quart, PharmD, Ardea's President and CEO. "We look forward to further evaluating RDEA806 and are on track to begin a Phase 2b study comparing once daily doses of RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients receiving background treatment with Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), in the third quarter of this year. A recently completed drug interaction study with RDEA806 and Truvada confirmed the lack of drug-drug interactions between these agents, paving the way for initiation of the Phase 2b study."

The Phase 2a randomized, double-blind, placebo-controlled trial evaluated the antiviral activity, pharmacokinetics, safety a
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... ELMSFORD, N.Y. , Nov. 26, 2014  BioScrip ® , ... M. Smith , President and Chief Executive Officer, will present at ... follows: , , , Date: , , , ... , , 2:50 p.m. EST , , , , Location: ... About BioScrip, Inc. ...
(Date:11/26/2014)... Calif. , Nov. 26, 2014  Aridis ... to produce novel therapies for infectious diseases, announced ... M.D., an internationally recognized key opinion leader in ... Company,s scientific advisory board. Founder and ... stated, "We believe Dr. Opal,s extensive experience investigating ...
(Date:11/26/2014)... CHARLOTTE, N.C. , Nov. 25, 2014  At ... San Antonio this October, KaVo Kerr Group ... Institute Technology Expo, offering attendees the opportunity to see ... to well-respected key opinion leaders deliver lectures on the ... Kerr Group products include the new DEXIS CariVu Caries ...
Breaking Medicine Technology:Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
(Date:11/27/2014)... November 27, 2014 According to a ... companies looking to break into the surgical robotics ... specialties, other than the MIS field dominated by Intuitive. ... the U.S. surgical robotics market by 2020. , ... Dr. Kamran Zamanian, CEO and President of iData. “System ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 An inventor ... an embarrassing fact of life, and she wants to ... few minutes later, I decided that there needed to ... she said. , Easy to use and producible in ... in a woman’s private areas throughout the day. It ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... vaccine appears to be safe and produces an immune system ... to early clinical trial results reported by the U.S. National ... clinical trial for the vaccine paves the way for field-testing ... Sierra Leone as early as January, said Dr. Anthony Fauci, ...
(Date:11/27/2014)... NV (PRWEB) November 27, 2014 Now ... shopping season has officially launched, Emassagechair.com has ... Cyber Monday Discount Event. , Negotiating on behalf ... with top massage chair brands, Emassagechair.com has generated significant ... best deals and biggest discounts yet. , Shoppers are ...
(Date:11/27/2014)... DC (PRWEB) November 27, 2014 “LAB.C” was ... which features the latest and coolest technology products available to ... conducted the product review and shared with viewers ... for iOS and Android devices. , Consumers love portability and ... Their Cable Case for the iPhone5 and 5S has ...
Breaking Medicine News(10 mins):Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2
... was wracked by a long-running civil conflict, suffer high ... a report said Friday. ,The report ... found that 35 percent of residents surveyed ranked high ... disorder and 39 percent for anxiety. ...
... a plush Bangkok ballroom one evening in May, hoteliers, ... foie gras, oysters and sushi while they talked about ... Alaskan king crab, French wine and melt-in-your-mouth Parma ham ... of putting Bangkok on the international culinary map. Although ...
... more damning indictment of the public health system in the ... it has been stated that adults// with serious mental illness ... than Americans overall. ,The gap has widened since ... by 10 to 15 years. ,"We're going in ...
... West Coast Eagles star Ben Cousins broke his silence for the ... confirm// that he has indeed a problem of substance abuse. ... rehabilitation centre for the past months. He was being treated for ... ,He did not disclose the name of the drug ...
... a brain disease similar to mad cow disease, according to ... Neurology's 59th Annual Meeting in Boston, April 28 – May ... and chronic wasting disease, are fatal and there is no ... animal eats the body parts of other animals contaminated with ...
... ridding diabetic patients of the superbug MRSA - by ... Andrew Boulton and his team used green bottle fly ... were contaminated with MRSA and found all but one ... much quicker than the 28-week duration for the conventional ...
Cached Medicine News:Health News:Indonesia's Acehnese Suffer High Rates of Mental Trauma 2Health News:Bangkok Lures Visitors With Its Growing Gourmet Scene 2Health News:Major Mental Disorders Cut Life Span by Ten to Fifteen Years 2Health News:Cousins Recovering from His Substance Abuse Problem 2Health News:Vaccine Prevents Prion Disease in Mice 2Health News:Maggots Rid Patients of MRSA 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: